Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hetal Gandhi

Internal Medicine Livonia, MI Medical Doctor

NPI 1396754453 CMS profile 108892

9216 Middlebelt Rd, Livonia, MI 48150

Open in the dashboard

General payments

$6,522

363 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hetal Gandhi of Livonia, MI is reported in the CMS Open Payments database as having received $6,522 across 363 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $657 35
2024 General $744 48
2023 General $959 60
2022 General $881 48
2021 General $1,254 54
2020 General $776 47
2019 General $1,251 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hetal Gandhi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hetal Gandhi were reported at $657. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hetal Gandhi Internal Medicine median Middle half National median
2019 $1,251 $159 $48–$570 $163
2020 $776 $119 $33–$402 $114
2021 $1,254 $135 $37–$521 $132
2022 $881 $141 $42–$496 $149
2023 $959 $149 $45–$519 $160
2024 $744 $154 $47–$537 $164
2025 $657 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,145 56 payments
  2. AbbVie, Inc. $898 59 payments
  3. Lilly USA, LLC $784 40 payments
  4. Pfizer Inc. $647 38 payments
  5. GlaxoSmithKline, LLC. $476 25 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $404 21 payments
  7. Novo Nordisk Inc $369 22 payments
  8. Amgen Inc. $300 17 payments
  9. Janssen Pharmaceuticals, Inc $279 15 payments
  10. Astellas Pharma US Inc $224 9 payments
  11. Other $996 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,411 361 payments
  2. Education $111 2 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $467 32 payments
  2. FARXIGA $447 21 payments
  3. TRELEGY ELLIPTA $353 16 payments
  4. MOUNJARO $328 16 payments
  5. UBRELVY $319 19 payments
  6. JARDIANCE $312 17 payments
  7. Ozempic $305 18 payments
  8. BREZTRI $301 12 payments
  9. AIRSUPRA $287 14 payments
  10. RYBELSUS $267 16 payments
  11. Other $5,596 349 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

3,043

Median for Internal Medicine: 777

Drug cost

$426,548

Median for Internal Medicine: $73,373

Branded share of claims

24.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 99 $86,225
Ozempic Semaglutide Brand 55 $64,539
Eliquis Apixaban Brand 49 $55,670
Jardiance Empagliflozin Brand 54 $46,814
Mounjaro Tirzepatide Brand 28 $28,818
Januvia Sitagliptin Phosphate Brand 23 $26,586
Myrbetriq Mirabegron Brand 32 $21,642
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $18,362
Xarelto Rivaroxaban Brand 18 $12,562
Trintellix Vortioxetine Hydrobromide Brand 22 $12,123

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$88,483

Of which drugs: $2,956

Medicare patients

225

Average age 72

Services billed

1,533

150 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 49%
Diabetes 31%
Chronic kidney disease 30%
Ischemic heart disease 20%
Depression 20%
COPD 16%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 35 35 $2,801

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$177 — —
VRAYLAR
$75 — —
QULIPTA
$60 — —
FARXIGA
$58 99 —
UBRELVY
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record